Article Text

OP0101 First Report of IL-38 in Systemic Lupus Erythematosus (SLE)
  1. J. Godsell,
  2. I. Rudloff,
  3. A. Hoi,
  4. M. Nold,
  5. E. Morand
  1. Monash University, Melbourne, Australia


Background The cytokine IL-38 (IL-1F10) is a member of the IL-1 superfamily, which binds to IL-36R. IL-38 polymoprhisms have been associated with spondylitis and rheumatoid arthritis, and while IL-38 function is poorly understood, it has been reported to inhibit Th17 responses.

Objectives Clinical associations of serum IL-38 have not been reported. Here, we investigated associations of serum IL-38 in SLE.

Methods Serum was obtained from patients with SLE (≥ACR 4) followed in a longitudinal cohort in which disease activity (SLEDAI-2k) and drug treatment details were recorded with each sample. IL-38 was quantified by ELISA.

Results 142 SLE patients (median age 42 (20-80) years, disease duration 103 (18-439) months) were studied at baseline, 115 of whom were also studied in two consecutive subsequent clinic visits. 28 age- and gender-matched healthy control individuals were also studied.

IL-38 (0-5928 pg/ml) was detectable in 128 (13.4%) baseline SLE samples. Mean serum IL-38 was significantly higher in SLE compared with controls (p=0.0031). Significantly higher IL-38 was observed in patients with active disease (SLEDAI ≥4, n=84, p=0.0438). Baseline IL-38 was significantly higher in patients with subsequent persistently active disease (PAD; Nikpour 2009) (p=0.0057), and time-adjusted mean IL-38 measured longitudinally was also significantly higher in patients with PAD (p=0.0226). Detectable IL-38 was associated with a 1.7 fold increased risk of PAD (RR=1.669, 95%CI 1.255-1.938, p=0.0096). Mean serum IL-38 was increased in patients with renal (p=0.0170) or CNS (p=0.0189) lupus, and detectable IL-38 was associated with increased risk of renal disease (RR=1.605, 95%CI 1.153-2.234, p=0.0280) and CNS disease (RR=2.233, 95%CI 1.174-4.249, p=0.0349).

Conclusions These data are the first report of IL-38 in SLE. Serum IL-38 is strongly associated with markers of adverse outcome including disease activity and renal and CNS disease. Further investigation of the role of IL-38 in SLE is justified.


  1. Nikpour, M., Urowitz, M. B., Ibañez, D., & Gladman, D.D. (2009). Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis & Rheumatism, 61(9), 1152–1158.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3594

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.